These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 19432497

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clodronate in the management of different musculoskeletal conditions.
    Frediani B, Giusti A, Bianchi G, Dalle Carbonare L, Malavolta N, Cantarini L, Saviola G, Molfetta L.
    Minerva Med; 2018 Aug; 109(4):300-325. PubMed ID: 29947493
    [Abstract] [Full Text] [Related]

  • 3. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL, Goa KL.
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [Abstract] [Full Text] [Related]

  • 4. [Use of clodronic acid in mineral metabolism conditions: state of the art in 2000].
    Brandi ML.
    Minerva Med; 2001 Aug; 92(4):251-68. PubMed ID: 11535969
    [Abstract] [Full Text] [Related]

  • 5. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders.
    Ghinoi V, Brandi ML.
    Expert Opin Pharmacother; 2002 Nov; 3(11):1643-56. PubMed ID: 12437497
    [Abstract] [Full Text] [Related]

  • 6. Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates.
    Muratore M, Quarta E, Grimaldi A, Calcagnile F, Quarta L.
    Drug Des Devel Ther; 2011 Nov; 5():445-54. PubMed ID: 22087064
    [Abstract] [Full Text] [Related]

  • 7. A tolerability and pharmacokinetic study of a new injectable formulation of disodium clodronate in healthy female volunteers.
    Poli G, Mariotti F, Corrado ME, Acerbi D.
    Eur J Drug Metab Pharmacokinet; 2004 Nov; 29(2):145-52. PubMed ID: 15230343
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients.
    Radicioni M, Cremonesi G, Baraldi E, Leuratti C, Mariotti F.
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):313-22. PubMed ID: 23357844
    [Abstract] [Full Text] [Related]

  • 9. Clodronate in the prevention and treatment of skeletal metastasis.
    Gulley J, Dahut WL.
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):221-30. PubMed ID: 15877520
    [Abstract] [Full Text] [Related]

  • 10. CLODRONATE: OLD DRUG, NEW USES.
    Saviola G, Abdi-Ali L, Povino MR.
    J Biol Regul Homeost Agents; 2015 Apr; 29(3):719-22. PubMed ID: 26403413
    [Abstract] [Full Text] [Related]

  • 11. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study.
    McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA.
    J Bone Miner Res; 2007 Jan; 22(1):135-41. PubMed ID: 17042717
    [Abstract] [Full Text] [Related]

  • 12. Clodronic acid in the treatment of postmenopausal osteoporosis.
    Tanakol R, Yarman S, Bayraktaroglu T, Boztepe H, Alagöl F.
    Clin Drug Investig; 2007 Jan; 27(6):419-33. PubMed ID: 17506592
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA.
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B, Milovanovic P, Amling M, Busse B.
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [Abstract] [Full Text] [Related]

  • 15. [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
    Endo Y, Funayama H, Yamaguchi K, Monma Y, Yu Z, Deng X, Oizumi T, Shikama Y, Tanaka Y, Okada S, Kim S, Kiyama T, Bando K, Shima K, Suzuki H, Takahashi T.
    Yakugaku Zasshi; 2020 Feb; 140(1):63-79. PubMed ID: 31902887
    [Abstract] [Full Text] [Related]

  • 16. Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis.
    Melchior R, Zabel B, Spranger J, Schumacher R.
    Eur J Pediatr; 2005 Jan; 164(1):22-7. PubMed ID: 15517381
    [Abstract] [Full Text] [Related]

  • 17. The Bisphosphonates Clodronate and Etidronate Exert Analgesic Effects by Acting on Glutamate- and/or ATP-Related Pain Transmission Pathways.
    Shima K, Nemoto W, Tsuchiya M, Tan-No K, Takano-Yamamoto T, Sugawara S, Endo Y.
    Biol Pharm Bull; 2016 Jan; 39(5):770-7. PubMed ID: 27150146
    [Abstract] [Full Text] [Related]

  • 18. Rationale for the use of clodronate in osteoporosis.
    Kanis JA, McCloskey EV, Sirtori P, Khan S, Fern D, Eyres K, Aaron J, Beneton MN.
    Osteoporos Int; 1993 Jan; 3 Suppl 2():S23-8. PubMed ID: 8481595
    [Abstract] [Full Text] [Related]

  • 19. Comparative appraisal of clodronate, aspirin and dexamethasone as agents reducing alendronate-induced inflammation in a murine model.
    Yu Z, Funayama H, Deng X, Kuroishi T, Sasano T, Sugawara S, Endo Y.
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):222-9. PubMed ID: 16176557
    [Abstract] [Full Text] [Related]

  • 20. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
    Sartori L, Adami S, Filipponi P, Crepaldi G.
    Aging Clin Exp Res; 2003 Aug; 15(4):271-83. PubMed ID: 14661816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.